This page shows the latest JAK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Cibinqo is a once-daily, oral Janus kinase 1 (JAK1) inhibitor used in adult patients living with moderate-to-severe atopic dermatitis who have not yet found relief in currently available
A decision on the JAK1/2 inhibitor is expected by 22 June 2021, Incyte said in a statement. ... However, the JAK inhibitor plus standard-of-care failed to prevent complications in this patient group in the RUXCOVID study.
the time it took to discharge patients from hospital following treatment with the IL-6 inhibitor. ... Novartis is also still conducting a phase 3 trial of its JAK1/2 inhibitor Jakavi (ruxolitinib) in COVID-19, with preliminary results from this study
Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... The reformulation could open up a new and very large treatment
Key candidates coming through late-stage development include JAK1 inhibitor abrocitinib for atopic dermatitis, a vaccine for Clostridium difficile infections, and vaccine against Clostridium difficile and Eli Lilly-partnered tanezumab, which
One of these potential blockbusters is JAK1 inhibitor filgotinib, which recently reported new, long-term phase 3 clinical data in rheumatoid arthritis.
More from news
Approximately 1 fully matching, plus 29 partially matching documents found.
Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... It will face competition mainly from generic statins and PCSK9
is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis.
Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... The first-in-class inhibitor of hypoxia- inducible factor-prolyl hydroxylase, or HIFPH, was approved in December
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... t the only oral JAK inhibitor developer with its eye on that particular prize.
Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease . ... 825. Takeda (Respiratory). AstraZeneca. Acquisition - asset. AZ buys Takeda global respiratory business including PDE 4
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...